Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children

Drilon, Alexander; W. Laetsch, Theodore; Kummar, Shivaani; G. DuBois, Steven; Lassen, Ulrik; D. Demetri, George; J. Nathenson, Michael; C. Doebele, Robert; F. Farago, Anna; S. Pappo, Alberto; Turpin, Brian; Dowlati, Afshin; S. Brose, Marcia; Mascarenhas, Leo; Federman, Noah; Berlin, Jordan; S. El‐Deiry, Wafik; S. Baik, Christina; F. Deeken, John; Boni, Valentina; Nagasubramanian, Ramamoorthy; H. Taylor, Matthew; R. Rudzinski, Erin; Meric‐Bernstam, Funda; Sohal, Davendra; Patrick, C.; E. Raez, Luis; F. Hechtman, Jaclyn; Benayed, Ryma; Ladanyi, Marc; B. Tuch, Brian; Ebata, Kevin; Cruickshank, Scott; Ku, Nora; C. Cox, Michael; S. Hawkins, Douglas; S. Hong, David; M. Hyman, David

doi:10.1056/nejmoa1714448

Public

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Published in New England Journal of Medicine • Feb 21, 2018

Authors:

Alexander Drilon

Theodore W. Laetsch

Shivaani Kummar

Abstract

BACKGROUND: Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors with these fusions. METHODS: We enrolled patie...

Subject

Trk receptor

Psychology

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!